Table 1 Demographic and clinical characteristics of our study sample (n = 17 eyes) at baseline (at intravitreal dexamethasone implant insertion).
Age (years, mean ± standard deviation) | 72.3 ± 7.1 |
Gender (N, %) | |
Male | 8 (47.1) |
Female | 9 (52.9) |
HbA1c (%, mean ± standard deviation) | 7.3 ± 0.7 |
Duration of diabetes mellitus (years, mean ± standard deviation) | 14.1 ± 5.3 |
Diabetic retinopathy status (N, %) | |
Non-proliferative | 14 (82.4) |
Proliferative (quiescent) | 3 (17.6) |
Hypertension (N, %) | 14 (82.4) |
Hyperlipidaemia (N, %) | 9 (52.9) |
Lens status (N, %) | |
Nuclear cataract | 10 (58.8%) |
Cortical cataract | 3 (17.6%) |
Posterior subcapsular cataract | 4 (23.6%) |
Previous treatment (N, %) | |
Intravitreal ranibizumab | 17 (100) |
Intravitreal dexamethasone implant | 6 (35.3) |
Focal/grid laser | 3 (17.6) |
Previous intravitreal injections (mean ± standard deviation, range) | 6.9 ± 5.8 (3–25) |
Best corrected visual acuity (ETDRS letters, mean ± standard deviation) | 42.3 ± 9.6 |
Central subfield thickness (μm, mean ± standard deviation) | 479.3 ± 89.7 |
Intraocular pressure (mmHg, mean ± standard deviation) | 14.9 ± 1.8 |
